Concepedia

Author

Florence Castan

Institut de Recherche en Cancérologie de MontpellierORCID

Also Known As

F Castan, F. Castan, Florence Castan, Florence Castan (149924), Lorenzo Fornaro

82

Publications

5.7K

Citations

20

H-Index

55

Concepts

All Affiliations

Institut de Recherche en Cancérologie de MontpellierInsermCentre Antoine LacassagneUniCancer GroupCentre Hospitalier Universitaire de Reims
FC

About

Florence Castan is an author at Institut de Recherche en Cancérologie de Montpellier specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

17

1K

2

Health Sciences

8

8

557

3

Cell Biology

3

3

91

4

Engineering

2

2

40

5

Biostatistics

1

1

16

Florence Castan

×

29

Publications

5.6K

Citations

20

H-Index

YearCitations

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar,

New England Journal of Medicine

2018

2.7K

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne,

The Lancet Oncology

2021

1.2K

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez,

JAMA Oncology

2022

284

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Thierry Conroy, Najib Lamfichekh, Pierre-Luc Etienne,

Journal of Clinical Oncology

2020

177

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Thierry Conroy, Florence Castan, Pierre-Luc Etienne,

Annals of Oncology

2024

144

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

Thierry Conroy, Pascal Hammel, Mohamed Hebbar,

Journal of Clinical Oncology

2018

138

Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial

D. Azria, O. Riou, Florence Castan,

EBioMedicine

2015

114

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

Simon Pernot, Magali Terme, Nina Radosevic‐Robin,

Gastric Cancer

2019

110

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Thierry Conroy, Pierre-Luc Etienne, Emmanuel Rio,

Journal of Clinical Oncology

2023

105

Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial

Philippe Rouanet, Éric Rullier, Bernard Lelong,

Diseases of the Colon & Rectum

2017

89

Page 1